A highly diverse team imagining the undiscovered

RENAL RESEARCH INSTITUTE

A highly diverse
team imagining
the undiscovered

ABOUT THE RENAL RESEARCH INSTITUTE

The heart of RRI’s capacity for innovation is our ability to examine complex problems through multiple lenses.

The Renal Research Institute (RRI) is an internationally recognized incubator of ideas, treatment processes, and technologies to improve the lives of kidney patients. RRI’s leadership in computational biomedicine and data analytics, as well as our access to a large patient population, accelerates the pace of scientific discoveries and their translation into applied medicine. Our team includes some of the brightest minds from around the world, who, along with their disciplinary expertise, bring a deep understanding of global healthcare issues and challenges.

Our Research

RRI’s pioneering leadership in computational biomedicine and data analytics drives breakthroughs, including the introduction of virtual clinical trials and smartphone-based diagnostics. Not only does our interdisciplinary approach foster wide-ranging research within the global framework of Fresenius Medical Care, it encourages collaboration with academic institutions in the United States, Asia, Europe, Latin America, and Africa.

Latest Research & News

Latest Research

  • Doris H Fuertinger, Lin-Chun Wang, David J Jörg, Lemuel Rivera Fuentes, Xiaoling Ye, Sabrina Casper, Hanjie Zhang, Ariella Mermelstein, Alhaji Cherif, Kevin Ho, Jochen G Raimann, Lela Tisdale, Peter Kotanko, Stephan Thijssen

    RESULTSThe intervention group showed an improved median percentage of hemoglobin measurements within target at 47% (IQR 39 to 58), with a 10 percentage points median difference between the two groups (95% CI: 3 to 16; P=0.008). The odds ratio of being within the hemoglobin target in the standard of care group compared to the group receiving the personalized ESA recommendations was 0.68 (95% CI: 0.51 to 0.92). The variability of hemoglobin levels decreased in the intervention group, with the percentage of patients experiencing fluctuating hemoglobin levels being 45% vs 82% in the standard of care group. ESA usage was reduced by about 25% in the intervention group.CONCLUSIONSOur results demonstrated an improved hemoglobin target attainment and variability by employing personalized ESA recommendations using the physiology-based anemia therapy assistance software.BACKGROUNDAnemia is common among hemodialysis patients. Maintaining stable hemoglobin levels within predefined target levels can be challenging, particularly in patients with frequent hemoglobin fluctuations both above and below the desired targets. We conducted a multi-center, randomized, controlled trial comparing our anemia therapy assistance software against a standard population-based anemia treatment protocol. We hypothesized that personalized dosing of erythropoiesis stimulating agents (ESA) improves hemoglobin target attainment.METHODSNinety-six patients undergoing hemodialysis and receiving methoxy polyethylene glycol-epoetin beta were randomized 1:1 to the intervention group (personalized ESA dose recommendations computed by the software) or the standard of care group for twenty-six weeks. The therapy assistance software combined a physiology-based mathematical model and a model predictive controller designed to stabilize hemoglobin levels within a tight target range (10 to 11 g/dl). The primary outcome measure was the percentage of hemoglobin measurements within the target. Secondary outcome measures included measures of hemoglobin variability and ESA utilization.

No Results Found

Latest News

No Results Found

Education

LATEST EPISODE

Solutes, Scaling, Sex: are we getting the dosing of dialysis, right?

Apr 27, 2022

Join Dr. Peter Kotanko, MD, FASN, Head of Biomedical Evidence Generation and Renal Research Institute, and John Daugirdas, MD, FACP, FASN, Clinical Professor of Medicine at the University of Illinois School of Medicine at Chicago, as they discuss aspects around dialysis patient prescription.